Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
Charles River Laboratories International, Inc. has unveiled its Alternative Methods Advancement Project (AMAP), a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
Smithers Avanza is granted renewal of full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), with “no recommendation for improvements.”
Replacing animal studies in drug development is impossible according to the European Commission, which has rejected a petition calling for a ban signed by 1.2m people.
British MPs have signed an anti-animal cruelty pledge which scientists warn would “cripple” disease research and outlaw 89% of preclinical animal research.
Testing the toxicity of drug candidates in animals is archaic and unreliable according to PETA, which joined preclinical CROs at SOT to put forward alternatives.
SNBL USA has invested in ‘social housing’ at its lab in Everett, Washington citing ‘recent reductions’ in US non-human primate lab capacity as the driver.
Arizona moved a step closer to excluding federally regulated research facilities from animal cruelty laws yesterday after the Senate National Resources, Infrastructure and Public Debt Committee voted in favour of such a move.
The threat posed by animal rights activists has been highlighted by an alleged arson attack on the Novartis’ CEO’s lodge, with one group saying their only regret is that he was not home when it burned.
Contract research firm Covance has been given the green light for its $100m (€77m) animal testing and drug candidate development facility in Chandler, Arizona, US.
Danish firm Novozymes has been honoured by animal rights
organisation PETA for its efforts to provide animal-free
bioprocessing methods aimed at cutting animal testing during drug
development.
Animal rights activists have continued their campaign of
intimidation after it was revealed the GlaxoSmithkline (GSK)
shareholders were sent letters demanding they sell any shares held
within the company.
Animal rights activists, who engage in acts of violence, could be
prosecuted under new anti-terror legislation proposals outlined by
the Government that aim to crack down on recent attacks on British
Universities with animal research...
The activities of animal extremists took a sinister turn as it was
revealed the broker to the drug company Phytopharm quit after a
bomb exploded beneath the car of one of the firm's executives.
In a defiant gesture to animal activists, Britain's pharmaceutical
companies have joined forces to launch a £4m research fund to
finance animal experiments in universities.
The reality of the violence of some UK animal activists became
apparent after GlaxoSmithKline (GSK), Europes's biggest drug maker,
warned that investment and jobs would be driven out of the country
by their actions.
The use of animal testing in pharmaceutical research and
development is to be revised after the UK government announced it
was to establish a national centre to reduce use and raise
standards of animal welfare, writes Wai Lang Chu.
The use of animal testing in pharmaceutical research and
development is to be revised after the UK government announced it
was to establish a national centre to reduce use and raise
standards of animal welfare.
The number of animals tests needed for new chemicals could be
reduced significantly by the use of assays tests developed by
researchers at the European Commission's Joint Research Centre. And
this should be welcome news for companies...
A UK-based animal rights group has passed video footage of alleged
animal cruelty at a facility in Germany run by US contract research
company Covance to the Ministry of Environment in
Northrhine-Westfalia.
The UK High Court has issued injunctions against a number of
individuals found to be involved in the harassment of staff working
for UK-based Japanese pharmaceutical companies.
